David Watson is the ABPI’s Director of Pricing and Reimbursement. He is primarily responsible for leading the
implementation of the 2014 Pharmaceutical Price Regulation Scheme (PPRS), the scheme covers the vast majority of branded medicines sold to the NHS and is negotiated by the ABPI on behalf of industry and the Department of Health. The scheme is now half way through its second year, and has involved the industry underwriting most of the growth in branded medicines, but in return for maintaining UK list prices, as well as a variety of commitments on access and uptake.
David also leads currently on ABPI’s NHS partnership focus, therapy groups, and input to the Accelerated Access Review (AAR). Previously David worked in consulting, focusing on global projects within the Pharma industry on brand marketing, launch planning and biosimilars. David spent much of his career with Pfizer, where he held a variety of UK and European roles across the business. He led work in European markets to establish new sales channels. In 2007 David led the Direct to Pharmacy (DTP) initiative which resulted in Pfizer breaking away from the traditional UK medicines supply model.